Table 3.
Multivariable analysis of the relative risk of death from pancreatic ductal adenocarcinoma (PDAC) by matrix metalloproteinase 8 (MMP-8) expression level in cancer cells, tumour-associated MMP-8 positive polymorphonuclear cells (PMNs) and plasma C-reactive protein (CRP) and clinicopathological characteristics.
| Hazard Ratio | 95% CI | p Value | |
|---|---|---|---|
| Age | 1.43 | 0.93–2.20 | 0.101 |
| Sex | 1.05 | 0.67–1.66 | 0.829 |
| T1 | 1 (reference) | 0.317 | |
| T2 | 0.61 | 0.29–1.30 | 0.203 |
| T3 | 0.52 | 0.22–1.22 | 0.132 |
| N0 | 1 (reference) | 0.001 | |
| N1 | 1.96 | 1.09–3.53 | 0.025 |
| N2 | 4.00 | 1.98–8.10 | <0.001 |
| Perivascular invasion | 1.63 | 1.02–2.61 | 0.043 |
| Adjuvant therapy | 0.62 | 0.40–0.97 | 0.038 |
| CA19-9 (kU/l, log10) | 1.26 | 1.00–1.58 | 0.047 |
| CRP ≥ 10 vs. <10 mg/L | 2.25 | 1.34–3.76 | 0.002 |
| MMP-8 = 1–3 vs. 0 | 0.33 | 0.16–0.68 | 0.003 |
| PMNS = 1–3 vs. 0 | 0.75 | 0.48–1.16 | 0.196 |